An audit to compare the drug Canagliflozin in clinical trials with real life outcomes has been launched.
The aim of the Canagliflozin Audit is to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials, the Association of British Clinical Diabetologists (ABCD) said. To read more, click here.